Viewing Study NCT02100618

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:59 AM
Ignite Modification Date: 2026-02-28 @ 11:26 PM
Study NCT ID: NCT02100618
Status: WITHDRAWN
Last Update Posted: 2015-07-20
First Post: 2014-03-27
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Infections, Papillomavirus View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Adolescents View
None Adults View
None Immunogenicity View
None 6.5 years View
None Safety View
None Antibody persistence View
None Human Papillomavirus (HPV) vaccine View